SCHEMBL7789691

SCHEMBL7789691

Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.66
KCNA3 P22001 2/20 0.66
CYP19A1 P11511 5/20 0.56
OPRK1 P41145 3/20 0.56
KCNH2 Q12809 3/20 0.56
HTR2A P28223 2/20 0.56
HTR2C P28335 2/20 0.56
NR1I2 O75469 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
TBXA2R P21731 2/20 0.56
CCKBR P32239 2/20 0.56
SLC6A3 Q01959 2/20 0.56
NR1H4 Q96RI1 2/20 0.56
CYP3A4 P08684 2/20 0.56
TSHR P16473 2/20 0.56
MEN1 O00255 1/20 0.56
SLC22A1 O15245 1/20 0.56
GMNN O75496 1/20 0.56
USP2 O75604 1/20 0.56
TRPM2 O94759 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7796676 0.83 CYP11B1 (0.46) KCNN4KCNA3CYP19A1OPRK1KCNH2
SCHEMBL41130 0.79 KCNN4 (1.00) KCNN4KCNA3CYP19A1OPRK1KCNH2
SCHEMBL29499525 0.79 KCNN4 (1.00) KCNN4KCNA3CYP19A1OPRK1KCNH2
SCHEMBL2360873 0.78 KCNN4 (0.57) KCNN4KCNA3CYP19A1OPRK1KCNH2
SCHEMBL2388992 0.74 KCNN4 (0.60) KCNN4KCNA3CYP19A1OPRK1KCNH2
SCHEMBL5479925 0.73 CYP19A1 (0.66) KCNN4KCNA3CYP19A1OPRK1KCNH2
Clotrimazole SCHEMBL29358270 0.72 CYP19A1 (1.00) KCNN4KCNA3CYP19A1OPRK1KCNH2
Clotrimazole SCHEMBL1062253 0.72 CYP19A1 (1.00) KCNN4KCNA3CYP19A1OPRK1KCNH2
SCHEMBL332191 0.72 KCNN4 (0.61) KCNN4KCNA3CYP19A1OPRK1KCNH2
SCHEMBL9720736 0.72 CYP19A1 (0.94) KCNN4KCNA3CYP19A1OPRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010011137-A1 Use of triphenylmethyl-1,2,3-triazoles URBAHNS KLAUS (DE) 2001-08-02 US claimed
US-20010011137-A1 Use of triphenylmethyl-1,2,3-triazoles URBAHNS KLAUS (DE) 2001-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010011137-A1 Use of triphenylmethyl-1,2,3-triazoles PNMT, NLN, TPMT KCNN4 2263/4885KCNA3 921/4885CYP19A1 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.